RECIST

RECIST (Response Evaluation Criteria In Solid Tumors) is a set of published rules that define when cancer patients improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatments. The main goal of RECIST is to provide a standardized method for assessing the response to treatments in solid tumors, for use in clinical trials.

History

The RECIST guidelines were first published in 2000 by a group of experts in the field of oncology. The guidelines were updated in 2009 to RECIST 1.1, which is the current version in use.

Methodology

The RECIST criteria are based on the sum of the longest diameter of target lesions. A minimum of two lesions are selected and measured at baseline. The sum of these measurements serves as a reference to further assess the tumor burden. The response to treatment is then categorized as follows:

• Complete Response (CR): Disappearance of all target lesions
• Partial Response (PR): At least a 30% decrease in the sum of the longest diameter of target lesions
• Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD
• Progressive Disease (PD): At least a 20% increase in the sum of the longest diameter of target lesions

Limitations

While RECIST has been widely adopted in clinical trials, it has several limitations. It does not account for changes in tumor density or the presence of new lesions. Furthermore, it is not applicable to all types of cancer, such as leukemia and lymphoma.

See Also

• Cancer
• Clinical trial
• Oncology
• Tumor

RECIST Resources
Latest articles Most recent articles Ongoing trials	Wikipedia